Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of evolutionarily conserved viral integration sites as safe harbors for human gene therapy.

iScience·2025
Same author

Selective Enrichment of Full Capsids of Adeno-Associated Virus.

ACS nano·2025
Same author

An Integrated Experimental and Modeling Approach for Crystallization of Complex Biotherapeutics.

Crystal growth & design·2025
Same author

Development of a Rapid Adeno-Associated Virus (AAV) Identity Testing Platform through Comprehensive Intact Mass Analysis of Full-Length AAV Capsid Proteins.

Journal of proteome research·2023
Same author

Mechanistic modeling explains the production dynamics of recombinant adeno-associated virus with the baculovirus expression vector system.

Molecular therapy. Methods & clinical development·2023
Same author

SP3-based host cell protein monitoring in AAV-based gene therapy products using LC-MS/MS.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2023

Related Experiment Video

Updated: Mar 5, 2026

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System
10:31

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System

Published on: January 13, 2022

10.5K

Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines.

Robert M Kotin1, Richard O Snyder2

  • 11 Gene Therapy Center, University of Massachusetts Medical School , Worcester, Massachusetts.

Human Gene Therapy
|March 30, 2017
PubMed
Summary
This summary is machine-generated.

Scalable Sf9 cell production offers a reliable, economical source of high-quality recombinant adeno-associated virus (rAAV) vectors. This advancement supports gene therapy development for widespread clinical applications and large patient populations.

Keywords:
AAV vectorSf9 cells

More Related Videos

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
05:51

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

2.8K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

38.1K

Related Experiment Videos

Last Updated: Mar 5, 2026

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System
10:31

Process Development for the Production and Purification of Adeno-Associated Virus AAV2 Vector using Baculovirus-Insect Cell Culture System

Published on: January 13, 2022

10.5K
Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
05:51

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

2.8K
Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

38.1K

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Molecular Biology

Background:

  • Recombinant adeno-associated virus (rAAV) vectors are crucial for gene therapy, but manufacturing challenges hinder clinical development.
  • Limited quantities and lot-to-lot variability of rAAV vectors impact safety, efficacy, and commercialization.
  • Current production methods face limitations in scalability and cost-effectiveness.

Purpose of the Study:

  • To address the challenges in producing high-quality, scalable recombinant adeno-associated virus (rAAV) vectors.
  • To highlight the Sf9 insect cell line as a viable platform for economical and large-scale rAAV production.
  • To provide an overview of the genetics, processes, and current system for Sf9 cell-based rAAV manufacturing.

Main Methods:

  • Utilized the Sf9 invertebrate cell line for recombinant adeno-associated virus (rAAV) vector production.
  • Developed and optimized genetics and processes for scalable rAAV manufacturing in Sf9 cells.
  • Characterized rAAV lots to ensure quality and consistency for clinical applications.

Main Results:

  • The Sf9 cell production platform provides a scalable and economical source of rAAV vectors.
  • Larger quantities of rAAV are now accessible, enabling gene therapy for diseases requiring high doses or large patient populations.
  • The Sf9 platform has successfully produced rAAV for clinical trials and the only licensed rAAV product.

Conclusions:

  • The Sf9 cell line offers a robust solution for overcoming rAAV manufacturing limitations.
  • This scalable production method is essential for advancing gene therapeutics for a broader range of diseases.
  • The Sf9 platform is critical for meeting the clinical and commercial demands of recombinant adeno-associated virus (rAAV) gene therapies.